At PharmaTell we keep Eyes on Strategic moves within the market. This week we're diving into Merck & Co's plans for the future. With the upcoming patent expiry for Keytruda, they are planning to bolster their pipeline with new products and indications via internal development and M&A.

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...